We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-2.94%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$119B
AUM Growth
-$2.4B
Cap. Flow
+$2.12B
Cap. Flow %
1.78%
Top 10 Hldgs %
24.78%
Holding
3,988
New
162
Increased
1,714
Reduced
1,756
Closed
200

Top Buys

Rank Stock Value
1
VOO icon
Vanguard S&P 500 ETF
VOO
+$630M
2
AGG icon
iShares Core US Aggregate Bond ETF
AGG
+$315M
3
JMBS icon
Janus Henderson Mortgage-Backed Securities ETF
JMBS
+$90.5M
4
META icon
Meta Platforms (Facebook)
META
+$59.8M
5
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$59.1M

Top Sells

Rank Stock Value
1
RTX icon
RTX Corp
RTX
+$99.6M
2
AAPL icon
Apple
AAPL
+$88.3M
3
MBB icon
iShares MBS ETF
MBB
+$85.4M
4
MTUM icon
iShares MSCI USA Momentum Factor ETF
MTUM
+$51.6M
5
CSCO icon
Cisco
CSCO
+$43.2M

Sector Composition

Rank Sector Weight
1 Technology 14.94%
2 Financials 8.89%
3 Healthcare 8.4%
4 Industrials 6.56%
5 Consumer Discretionary 5.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PPBT
3726
Purple Biotech
PPBT
$2.38M
$13.1K ﹤0.01%
55
– –
ORGN
3727
DELISTED
Origin Materials
ORGN
$12.9K ﹤0.01%
337
-203
-38% -$15.9K
EGLX
3728
DELISTED
Enthusiast Gaming Holdings Inc. Common Stock
EGLX
$12.7K ﹤0.01%
38,231
– –
ACHL
3729
DELISTED
Achilles Therapeutics
ACHL
$11.9K ﹤0.01%
13,105
+9
+0.1% +$9
LXRX icon
3730
Lexicon Pharmaceuticals
LXRX
$1.08B
$11.8K ﹤0.01%
10,841
-232
-2% -$407
FTH
3731
Faeth Therapeutics
FTH
$786M
$11.2K ﹤0.01%
700
– –
MLSS icon
3732
Milestone Scientific
MLSS
$42.5M
$11K ﹤0.01%
12,000
-8,000
-40% -$8.42K
NVTA
3733
DELISTED
Invitae Corporation
NVTA
$10.9K ﹤0.01%
18,025
-11,743
-39% -$12.2K
JOB icon
3734
GEE Group
JOB
$21.9M
$10.7K ﹤0.01%
18,000
– –
ACB
3735
Aurora Cannabis
ACB
$224M
$10.3K ﹤0.01%
1,760
-87
-5% -$506
DCFC
3736
DELISTED
Tritium DCFC Limited Ordinary Shares
DCFC
$9.83K ﹤0.01%
162
+5
+3% +$952
PVLA
3737
Palvella Therapeutics
PVLA
$2.24B
$8.94K ﹤0.01%
375
– –
SENS icon
3738
Senseonics Holdings Inc
SENS
$419M
$8.88K ﹤0.01%
735
-57
-7% -$787
KGC icon
3739
CALL
Kinross Gold
KGC
$32.9B
$8.8K ﹤0.01%
2,200
– –
AKTS
3740
DELISTED
Akoustis Technologies Inc
AKTS
$8.58K ﹤0.01%
+11,391
New +$21K
ADAP
3741
DELISTED
Adaptimmune Therapeutics
ADAP
$8.09K ﹤0.01%
10,369
-80
-0.8% -$67
AMRS
3742
CALL
DELISTED
Amyris Inc.
AMRS
$8K ﹤0.01%
1,000
– –
GOEV
3743
DELISTED
Canoo Inc. Class A Common Stock
GOEV
$6.57K ﹤0.01%
+29
New +$7.31K
IMPL
3744
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$6.24K ﹤0.01%
14,500
– –
GYRE icon
3745
Gyre Therapeutics
GYRE
$717M
$6.22K ﹤0.01%
860
– –
INO icon
3746
Inovio Pharmaceuticals
INO
$77.8M
$6.02K ﹤0.01%
1,290
+17
+1% +$94
FTNT icon
3747
PUT
Fortinet
FTNT
$119B
$6K ﹤0.01%
+100
New +$6.62K
TMQ
3748
Trilogy Metals
TMQ
$677M
$5.71K ﹤0.01%
+11,656
New +$5.93K
LMDX
3749
DELISTED
LumiraDx Limited Common Shares
LMDX
$4.34K ﹤0.01%
18,478
-5,500
-23% -$2.08K
BLPH
3750
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$3.98K ﹤0.01%
10,000
-1,097
-10% -$540
148 149
150
151 152

Similar funds

RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
PI
PEAK6 Investments Chicago, Illinois $44.8B AUM 19.99% 1-Year Est. Return
ECU
Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AA
Axiom Advisory San Diego, California $10.7B AUM 25.51% 1-Year Est. Return
SA
SpiderRock Advisors Wilimington, Delaware $6.29B AUM
WPL
Winder Pte Ltd Singapore $5.59B AUM 41.5% 1-Year Est. Return
ECU
Eisler Capital (US) New York $4.67B AUM 35.2% 1-Year Est. Return

Raymond James & Associates's Q3 2023 Portfolio in Review

As of Q3 2023, Raymond James & Associates held 3,988 positions worth $119B, down 2% from $121B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Raymond James & Associates's Q3 2023 filing shows 162 new, 1,714 increased, 1,756 reduced and 200 closed positions. Its largest new stake was InterContinental Hotels: 102,555 shares worth $7.67M. The largest sale was RTX Corp, an estimated $99.6M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 15% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q3 2023 buy was InterContinental Hotels: 102,555 shares worth $7.67M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q3 2023, an estimated $630M increase.
  • Raymond James & Associates's biggest Q3 2023 reduction was RTX Corp, cutting an estimated $99.6M.
  • Raymond James & Associates fully exited Magellan Midstream Partners, L.P. in Q3 2023, selling an estimated $17.3M.
  • Raymond James & Associates's ten largest holdings make up 25% of its $119B portfolio in Q3 2023.
  • Raymond James & Associates opened 162 new positions and closed 200 in Q3 2023.
  • Raymond James & Associates's portfolio value fell 2% quarter-over-quarter to $119B.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.